James Nguyen
Memorial Sloan Kettering Cancer Center
4 Papers
6 Citations
James Nguyen is an academic researcher from Memorial Sloan Kettering Cancer Center. The author has contributed to research in topics: Lenalidomide & Multiple myeloma. The author has an hindex of 1, co-authored 3 publications.
Chat about Author
Papers
Immunophenotypic evidence for reactive polyclonal marrow plasmacytosis in multiple myeloma patients receiving lenalidomide maintenance.
Hani Hassoun,Mikhail Roshal,Joshua K. Sabari,James Nguyen,Qi Gao,Sean M. Devlin,Heather Landau,Nikoletta Lendvai,David J. Chung,Alexander M. Lesokhin,Neha Korde,Sham Mailankody,Ahmet Dogan,Sergio Giralt,C. Ola Landgren +14 more
TL;DR: This research presents a novel, scalable, scalable and scalable approach that allows for real-time decision-making in the selection of patients for bone marrow transplantation and describes its use in personalized medicine.
5
Multiple myeloma with simultaneous cutaneous and central nervous system involvement.
James Nguyen,Hani Hassoun +1 more
TL;DR: Cutaneous involvement in multiple myeloma is an extremely rare occurrence that is underrecognized and akin CNS involvement, typically occurs late in the disease course, and is associated with an aggressive biology.
2
Vitiligo Following Autologous Hematopoietic Stem Cell Transplantation.
James Nguyen,Navdeep Singh,Salma Afifi,Sergio Giralt,Mario E. Lacouture,Klaus J. Busam,Hani Hassoun +6 more
Abstract: Vitiligo, a depigmenting dermatosis is characterized by the disappearance of melanocytes in the epidermis and thought to be an autoimmune condition1. While it has been reported in a small number of patients following allogeneic hematopoietic stem cell transplantation (HSCT) and attributed to T-cell deregulation2, 3, its occurrence after autologous HSCT has only been reported twice in the English literature4, 5. Therefore, the etiological correlation remains uncertain. In this report, we describe a case of significant hypopigmentation consistent with vitiligo, developing in a patient with multiple myeloma following autologous HSCT.
2
Continuous induction with lenalidomide/dexamethasone versus autologous stem cell transplantation in newly diagnosed multiple myeloma: a case for response-adapted approach
Oscar B Lahoud,Heather Landau,James Nguyen,Sean M. Devlin,Nikoletta Lendvai,J. Weltz,Tumininu Ayorinde,David J. Chung,Alexander M. Lesokhin,Tarun Kewalramani,Neha Korde,Sham Mailankody,Ola Landgren,Sergio Giralt,Raymond L. Comenzo,Hani Hassoun +15 more
TL;DR: An extended follow-up analysis of a phase 2 trial that randomized transplant-eligible patients with NDMM who responded to induction to continued induction or ASCT suggests the need for prospective trials incorporating response-adapted therapeutic approaches to NDMM.
1